Clinical trial
A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation…
NCT00378690 · Astellas Pharma Inc, Industry · Completed
Key facts
| NCT number | NCT00378690 |
|---|---|
| Title | A Phase IIIb Study of Intermittent Versus Continuous Hormone Deprivation Treatment With ELIGARD |
| Official title | A Phase IIIb Randomized Study of Intermittent Versus Continuous Androgen Deprivation Therapy Using ELIGARD 22.5 mg 3-month Depot in Subjects With Relapsing and Locally Advanced Prostate Cancer Who Are Responsive to Such Therapy |
| Acronym | ICELAND |
| Lead sponsor | Astellas Pharma Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | leuprorelin acetate |
| Enrollment | 706 |
| Start date | Mar 1, 2006 |
| Primary completion | Jun 1, 2011 |
| Completion | Dec 1, 2012 |
| First posted | Sep 21, 2006 |
| Last update posted | Jun 4, 2014 |
| Countries | Belgium, Czechia, Finland, France, Germany, Hungary, Italy, Russia, Slovakia, Spain |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: